Abreos Biosciences Announces Partnership with CLIA/CAP Certified Laboratory, ResearchDx

Commercial assay for Tysabri (Natalizumab) developed to enable physicians to make data driven decisions on how to optimize the infusion schedule for their multiple sclerosis patients. SAN DIEGO, Calif. (PRWEB) August 30, 2018 — Abreos Biosciences, a leader in the precision dosing of biological therapeutics, is pleased to announce a collaboration with ResearchDx, a recognized […]

Read More